NCT00267501

Brief Summary

The purpose of this study is to elucidate the mechanisms underlying eosinophil growth, survival, migration, and function and to investigate and further characterize the pathophysiology of, clinical manifestations of, and spectrum of disease severity of eosinophilic inflammation in humans.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
5,000

participants targeted

Target at P75+ for all trials

Timeline
288mo left

Started May 2005

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress47%
May 2005Jan 2050

Study Start

First participant enrolled

May 1, 2005

Completed
8 months until next milestone

First Submitted

Initial submission to the registry

December 15, 2005

Completed
6 days until next milestone

First Posted

Study publicly available on registry

December 21, 2005

Completed
44.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2050

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2050

Last Updated

September 17, 2025

Status Verified

September 1, 2025

Enrollment Period

44.7 years

First QC Date

December 15, 2005

Last Update Submit

September 11, 2025

Conditions

Eosinophilic Gastrointestinal Disease Eosinophilic Inflammatory DiseaseFood Allergy

Keywords

Eosinophilic Disorders

Eligibility Criteria

Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients with eosinophilic disorders and patients without eosinophilic disorders to serve as normal controls

You may qualify if:

  • Signed informed consent obtained from the patient or parent/guardian. Assent will be obtained from all minors 11 years of age and older.
  • Carrying a diagnosis of eosinophilic gastrointestinal disease, eosinophilic inflammatory disease, or food allergy OR family member, or normal control

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Cincinnati Children's Hospital Medical Center

Cincinnati, Ohio, 45229-3039, United States

RECRUITING

MeSH Terms

Conditions

Food HypersensitivityEosinophilia

Condition Hierarchy (Ancestors)

Hypersensitivity, ImmediateHypersensitivityImmune System DiseasesLeukocyte DisordersHematologic DiseasesHemic and Lymphatic Diseases

Study Officials

  • Marc E. Rothenberg, M.D., Ph.D.

    Cincinnati Children's Hospital Medical Center

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Bliss Magella

CONTACT

513-636-7832bliss.magella@cchmc.org

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 15, 2005

First Posted

December 21, 2005

Study Start

May 1, 2005

Primary Completion (Estimated)

January 1, 2050

Study Completion (Estimated)

January 1, 2050

Last Updated

September 17, 2025

Record last verified: 2025-09

Locations

US(1)